Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer

Charlotte C. Sun, Diane C. Bodurka, Candice B. Weaver, Rafia Rasu, Judith K. Wolf, Michael W. Bevers, Judith A. Smith, J. Taylor Wharton, Edward B. Rubenstein

Research output: Contribution to journalArticlepeer-review

241 Scopus citations


Goals of work: Although many patients with ovarian cancer achieve favorable responses to primary chemotherapy, the majority of women will experience recurrence of their cancer. Selection of second- or third-line chemotherapy ultimately depends on patient preferences for different side effects. To better understand this process, we evaluated preferences and symptom distress in patients with ovarian cancer. Patients and methods: A total of 70 women with ovarian cancer who had previously received at least three cycles of platinum-based chemotherapy and currently undergoing chemotherapy for newly diagnosed or recurrent disease were interviewed in an outpatient chemotherapy clinic. The patients were asked to rank order 27 health states using a modified visual analog scale and to complete the Memorial Symptom Assessment Scale (MSAS). Main results: Most favorable health states included perfect health, clinical remission and complete control of chemotherapy-induced nausea and vomiting (CINV). Least favorable health states included more severe CINV health states and death. Patients on first-line chemotherapy had less symptom distress, and rated sexual dysfunction, fatigue and memory loss more favorably than patients on second- or third-line chemotherapy (P<0.05). Married patients generally had less symptom distress compared to patients who were not married, but married patients indicated more distress with sexual dysfunction (P=0.04). Married patients rated alopecia less favorably than unmarried patients (P=0.03), but married patients viewed certain CINV health states more favorably (P=0.02-0.04). Conclusions: CINV remains one of the most dreaded side effects of chemotherapy. Separate preference profiles exist for patients with newly diagnosed and recurrent disease, as well as for married versus unmarried patients. While MSAS scores and VAS rankings showed consistency across some health states, this was not true for CINV, suggesting that current symptom status may only influence patient preferences for selected side effects.

Original languageEnglish
Pages (from-to)219-227
Number of pages9
JournalSupportive Care in Cancer
Issue number4
StatePublished - Apr 2005


  • Chemotherapy side effects
  • Ovarian cancer
  • Patient preferences
  • Symptom assessment
  • Visual analog scale


Dive into the research topics of 'Rankings and symptom assessments of side effects from chemotherapy: Insights from experienced patients with ovarian cancer'. Together they form a unique fingerprint.

Cite this